A Panoramic View on Neurodegeneration, Its Connection with Microbiota and Its Therapeutics
DOI:
https://doi.org/10.32628/IJSRST25126403Keywords:
Neurodegeneration, Parkinsonism, Alzheimer's disease, Gut brain axis, antioxidantsAbstract
Neurodegenerative diseases are becoming one of the leading causes of death globally and silently affecting the society. The major cause of neurodegeneration is accumulation of free radicals and reactive oxygen species that can induces cellular events of mitochondrial damage, activation of other necrotic cascades that results into neuronal death. One of the underlying causes of this accumulation is aging and reduced antioxidants in the body as well as the novel finding suggests that imbalance in Gut Brain Axis (GBA) is the major cause. Microbial gut flora plays an important role in balancing these free radicals as well as neural homeostasis. Due to aging and other causes this axis is damaged resulting into failure in repair mechanism against the neuronal death. Current therapy for neurodegeneration fails to treat the condition and only managing the symptoms because the therapy is intended for symptomatic cure only. Recent advances in therapy of neurodegeneration involves the repairing of system from root cause, by the means of gene therapy, immunomodulation, anti-oxidants therapy, balancing gut microbiota which can balance the Gut Brain Axis and thus can helpful to control several conditions, use of novel drug delivery system to improve the effectiveness of available treatments like nano-gel, nano-suspension, hydrogels, etc.
Downloads
References
Parkinson’s Disease in 204 Countries/Territories From 1990 to 2019. Front. Public Heal. (2021) 9, 776847. https://doi.org/10.3389/FPUBH.2021.776847/FULL.
Gadhave, D., Gupta, A., Khot, S., Tagalpallewar, A., Kokare, C., Nose-to-brain delivery of paliperidone palmitate poloxamer-guar gum nanogel: Formulation, optimization and pharmacological studies in rats. Ann. Pharm. Françaises (2023) 81, 315–333. https://doi.org/10.1016/J.PHARMA.2022.08.010.
Niazi, S.K., Non-Invasive Drug Delivery across the Blood–Brain Barrier: A Prospective Analysis. Pharmaceutics 15. https://doi.org/10.3390/PHARMACEUTICS15112599.
Olufunmilayo, E.O., Gerke-Duncan, M.B., Holsinger, R.M.D., Oxidative Stress and Antioxidants in Neurodegenerative Disorders, 2023, Vol. 12, 517 12 Antioxidants 517. https://doi.org/10.3390/ANTIOX12020517
Sayre, L.M., Perry, G., Smith, M.A.,. Oxidative stress and neurotoxicity. Chem. Res. Toxicol. 21, 172–188. 2008 https://doi.org/10.1021/TX700210J/ASSET/IMAGES/LARGE/TX-2007-00210J_0001.JPEG
Singh, A., Kukreti, R., Saso, L., Kukreti, S., Oxidative Stress: A Key Modulator in Neurodegenerative Diseases. Molecules 24. 2019 https://doi.org/10.3390/MOLECULES24081583.
Ashraf, GM et al., Protein misfolding and aggregation in Alzheimer’s disease and type 2 diabetes mellitus. CNS Neurol. Disord. Drug Targets 13, 1280. https://doi.org/10.2174/1871527313666140917095514.
Khanam, H., Ali, A., Asif, M., Shamsuzzaman, Neurodegenerative diseases linked to misfolded proteins and their therapeutic approaches: A review. Eur. J. Med. Chem. (2016) 124, 1121–1141. https://doi.org/10.1016/J.EJMECH.2016.08.006.
T¨onnies, E., Trushina, E., Oxidative Stress, Synaptic Dysfunction, and Alzheimer’s Disease. J. Alzheimer’S. Dis. (2017) 57, 1105. https://doi.org/10.3233/JAD-161088.
Ahmad MA et al, Neuro-inflammation: a potential risk for dementia. Int. J. Mol. Sci. (2022) 23. https://doi.org/10.3390/IJMS23020616.
Ransohoff, RM et al. Neuroinflammation: Ways in Which the Immune System Affects the Brain. Neurotherapeutics (2015) 12, 896. https://doi.org/10.1007/S13311-015-0385-3.
Goldmann T et al, A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation, 2013 1611 Nat. Neurosci. 16, 1618–1626. https://doi.org/10.1038/nn.3531.
Triantafyllakou, I., Clemente, N., Khetavat, R.K., Dianzani, U., Tselios, T., Development of PLGA Nanoparticles with a Glycosylated Myelin Oligodendrocyte Glycoprotein Epitope (MOG35-55) against Experimental Autoimmune Encephalomyelitis (EAE). Mol. Pharm. (2022) 19, 3795–3805. https://doi.org/10.1021/ACS.MOLPHARMACEUT.2C00277.
Erdo F et al, Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res. Bull. (2018) 143, 155–170. https://doi.org/10.1016/J.BRAINRESBULL.2018.10.009.
Lamptey, R.N.L., Chaulagain, B., Trivedi, R., Gothwal, A., Layek, B., Singh, J., A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics. Int. J. Mol. Sci. 2022b. 23 https://doi.org/10.3390/IJMS23031851.
Ow, S.Y., Dunstan, D.E., A brief overview of amyloids and Alzheimer’s disease. Protein Sci. 2014. 23, 1315–1331. https://doi.org/10.1002/PRO.2524.
Breijyeh, Z., Karaman, R., Comprehensive review on Alzheimer’s disease: causes and treatment. Molecules 2020. 25. https://doi.org/10.3390/MOLECULES25245789.
Hogan, DB et al., Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia. CMAJ 2008. 179, 1019–1026. https://doi.org/10.1503/CMAJ.081103.
Gepshtein, S., Li, X., Snider, J., Plank, M., Lee, D., Poizner, H., Dopamine function and the efficiency of human movement. J. Cogn. Neurosci. 2014. 26, 645–657. https://doi.org/10.1162/JOCN_A_00503.
Khatri, D.K., Choudhary, M., Sood, A., Singh, S.B., Anxiety: An ignored aspect of Parkinson’s disease lacking attention. Biomed. Pharmacother. 2020. 131, 110776 https://doi.org/10.1016/J.BIOPHA.2020.110776.
JC, G., RA, B., The Differential Diagnosis of Parkinson’s Disease. Neurology 2018. 43, S1–S11. https://doi.org/10.15586/CODONPUBLICATIONS. PARKINSONS DISEASE. 2018. CH6.
Kulisevsky, J., Pharmacological management of Parkinson’s disease motor symptoms: update and recommendations from an expert. S1–S10 Rev. Neurol. 2022. 75. https://doi.org/10.33588/RN.75S04.2022217.
Mack, J., Marsh, L., Parkinson’s Disease: Cognitive Impairment. Focus (Am. Psychiatr. Publ. ). 2017. 15, 42–54. https://doi.org/10.1176/APPI.FOCUS.20160043.
Jankovic, J., Aguilar, L.G., Current approaches to the treatment of Parkinson’s disease. Neuropsychiatr. Dis. Treat. 2008. 4, 743–757. https://doi.org/10.2147/NDT.S2006.
Coles, A., Newer therapies for multiple sclerosis. Ann. Indian Acad. Neurol. 2015. 18, S30–S34. https://doi.org/10.4103/0972-2327.164824.
Klineova, S., Lublin, F.D., Clinical Course of Multiple Sclerosis. Cold Spring Harb. Perspect. Med. 2018. 8 https://doi.org/10.1101/CSHPERSPECT.A028928.
Sugandhi, V.V et al., Pharmacokinetics of vitamin dosage forms: A complete overview. Food Sci. Nutr. 2024. 12, 48–83. https://doi.org/10.1002/FSN3.3787.
Eva, L et al., A Comprehensive Review on Neuroimmunology: Insights from Multiple Sclerosis to Future Therapeutic Developments. Biomedicines 2023 11. https://doi.org/10.3390/BIOMEDICINES11092489.
Dargahi, N., Katsara, M., Tselios, T., Androutsou, M.E., De Courten, M., Matsoukas, J., Apostolopoulos, V., 2017. Multiple sclerosis: immunopathology and treatment update. Brain Sci. 7 https://doi.org/10.3390/BRAINSCI7070078.
Roos, R.A.C., Huntington’s disease: A clinical review. Orphanet J. Rare Dis. 2010. 5, 1–8. https://doi.org/10.1186/1750-1172-5-40/TABLES/5.
Schulte, J., Littleton, J.T., The biological function of the Huntingtin protein and its relevance to Huntington’s Disease pathology. Curr. Trends Neurol. 2011. 5, 65–78.
Saudou, F., Humbert, S., The Biology of Huntingtin. Neuron 2016. 89, 910–926. https://doi.org/10.1016/J.NEURON.2016.02.003.
Schneider, S.A., Bird, T., Huntington’s Disease, Huntington’s Disease Look-Alikes↱, and Benign Hereditary Chorea: What’s New? Mov. Disord. Clin. Pract. 2016. 3, 342–354. https://doi.org/10.1002/MDC3.12312.
McGarry, A et al., Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease. J. Huntingt. Dis. 2020. 9, 173–184. https://doi.org/10.3233/JHD-190393.
Zarei, S. et al., A comprehensive review of amyotrophic lateral sclerosis. Surg. Neurol. Int. 2015. 6 https://doi.org/10.4103/2152-7806.169561.
Masrori, P., Damme, P.Van, Amyotrophic lateral sclerosis: a clinical review 2020. 1918–1929. https://doi.org/10.1111/ene.14393
Rg, M., Jd, M., Dh, M., Rg, M., Jd, M., Dh, M., Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) 2012.
Neupane, P. et al, Investigating Edaravone Use for Management of Amyotrophic Lateral Sclerosis (ALS): A Narrative Review. Cureus 15. 2023. https://doi.org/10.7759/CUREUS.33746.
Hogden, A., Foley, G., Henderson, R.D., James, N., Aoun, S.M., Amyotrophic lateral sclerosis: improving care with a multidisciplinary approach. J. Multidiscip. Healthc. 2017. 10, 205–215. https://doi.org/10.2147/JMDH.S134992.
Thursby, E.; Juge, N. Introduction to the Human Gut Microbiota. Biochem. J, 2017., 474, 1823–1836.
Cho, I.; Blaser, M.J. The Human Microbiome: At the Interface of Health and Disease. Nat. Rev. Genet. 2012, 13, 260–270.
Yatsunenko, T. et al., Human Gut Microbiome Viewed across Age and Geography. Nature 2012, 486, 222–227.
Hills, R.D.; Pontefract, B.A.; Mishcon, H.R.; Black, C.A.; Sutton, S.C.; Theberge, C.R. Gut Microbiome: Profound Implications for Diet and Disease. Nutrients 2019, 11, 1613.
Eckburg, P.B.; Bik, E.M.; Bernstein, C.N.; Purdom, E.; Dethlefsen, L.; Sargent, M.; Gill, S.R.; Nelson, K.E.; Relman, D.A. Diversityof the Human Intestinal Microbial Flora. Science 2005, 308, 1635–1638.
Suganya, K.; Koo, B.S. Gut-Brain Axis: Role of Gut Microbiota on Neurological Disorders and How Probiotics/Prebiotics Beneficially Modulate Microbial and Immune Pathways to Improve Brain Functions. Int. J. Mol. Sci. 2020, 21, 7551.
Carabotti, M.; Scirocco, A.; Maselli, M.A.; Severi, C. The Gut-Brain Axis: Interactions between Enteric Microbiota, Central and Enteric Nervous Systems. Ann. Gastroenterol. 2015, 28, 203–209.
Collins, S.M.; Surette, M.; Bercik, P. The Interplay between the Intestinal Microbiota and the Brain. Nat. Rev. Microbiol. 2012, 10, 735–742.
Zhu, S.; Jiang, Y.; Xu, K.; Cui, M.; Ye,W.; Zhao, G.; Jin, L.; Chen, X. The Progress of Gut Microbiome Research Related to Brain Disorders. J. Neuroinflamm. 2020, 17, 25.
Ghaisas, S.; Maher, J.; Kanthasamy, A. Gut Microbiome in Health and Disease: Linking the Microbiome-Gut-Brain Axis and Environmental Factors in the Pathogenesis of Systemic and Neurodegenerative Diseases. Pharmacol. Ther. 2016, 158, 52–62.
Hoban, A.E.; Stilling, R.M.; Ryan, F.J.; Shanahan, F.; Dinan, T.G.; Claesson, M.J.; Clarke, G.; Cryan, J.F. Regulation of Prefrontal Cortex Myelination by the Microbiota. Transl. Psychiatry 2016, 6, e774.
Tran, S.M.S.; Hasan Mohajeri, M. The Role of Gut Bacterial Metabolites in Brain Development, Aging and Disease. Nutrients 2021, 13, 732.
Furness, J.B.; Callaghan, B.P.; Rivera, L.R.; Cho, H.J. The Enteric Nervous System and Gastrointestinal Innervation: Integrated Local and Central Control. Adv. Exp. Med. Biol. 2014, 817, 39–71.
Nezami, B.G.; Srinivasan, S. Enteric Nervous System in the Small Intestine: Pathophysiology and Clinical Implications. Curr. Gastroenterol. Rep. 2010, 12, 358–365.
Fleming, M.A.; Ehsan, L.; Moore, S.R.; Levin, D.E. The Enteric Nervous System and Its Emerging Role as a Therapeutic Target. Gastroenterol. Res. Pract. 2020, 8024171.
Ma, Q.; Xing, C.; Long,W.;Wang, H.Y.; Liu, Q.;Wang, R.F. Impact of Microbiota on Central Nervous System and Neurological Diseases: The Gut-Brain Axis. J. Neuroinflamm. 2019, 16, 53.
Tang, H.; Chen, X.; Huang, S.; Yin, G.;Wang, X.; Shen, G. Targeting the Gut–Microbiota–Brain Axis in Irritable Bowel Disease to Improve Cognitive Function—Recent Knowledge and Emerging Therapeutic Opportunities. Rev. Neurosci. 2023.
Jain, T.; Li, Y.-M. Gut Microbes Modulate Neurodegeneration. Science (1979) 2023, 379, 142–143.
Gulliver, E.L.; Young, R.B.; Chonwerawong, M.; D’Adamo, G.L.; Thomason, T.; Widdop, J.T.; Rutten, E.L.; Rossetto Marcelino, V.; Bryant, R.V.; Costello, S.P.; et al. Review Article: The Future of Microbiome-Based Therapeutics. Aliment. Pharmacol. Ther. 2022, 56, 192–208.
Misra, S.; Mohanty, D. Psychobiotics: A New Approach for Treating Mental Illness? Crit. Rev. Food Sci. Nutr. 2019, 59, 1230–1236.
Saulnier, D.M.; Ringel, Y.; Heyman, M.B.; Foster, J.A.; Bercik, P.; Shulman, R.J.; Versalovic, J.; Verdu, E.; Dinan, T.G.; Hecht, G.; et al. The Intestinal Microbiome, Probiotics and Prebiotics in Neuro-gastroenterology. Gut Microbes 2013, 4, 17–27.
Gowing, G., Svendsen, S., Svendsen, C.N., 2017. Ex vivo gene therapy for the treatment of neurological disorders. Prog. Brain Res. 230, 99–132. https://doi.org/10.1016/BS.PBR.2016.11.003.
Savi´c, N., Schwank, G., 2016. Advances in therapeutic CRISPR/Cas9 genome editing. Transl. Res. 168, 15–21. https://doi.org/10.1016/J.TRSL.2015.09.008.
Ling, Q., Herstine, J.A., Bradbury, A., Gray, S.J., 2023. AAV-based in vivo gene therapy for neurological disorders. Nat. Rev. Drug Discov. 22, 789–806. https://doi.org/10.1038/S41573-023-00766-7.
Mortada, I., Farah, R., Nabha, S., Ojcius, D.M., Fares, Y., Almawi, W.Y., Sadier, N.S., 2021. Immunotherapies for Neurodegenerative Diseases. Front. Neurol. 12, 654739 https://doi.org/10.3389/FNEUR.2021.654739/BIBTEX.
Shin, J., Kim, H.J., Jeon, B., Immunotherapy Targeting Neurodegenerative Proteinopathies: α-Synucleinopathies and Tauopathies. J. Mov. Disord. 2020. 13, 11. https://doi.org/10.14802/JMD.19057.
Valera, E., Masliah, E., Immunotherapy for neurodegenerative diseases: focus on α synucleino-pathies. Pharmacol. Ther. 2013. 138, 311–322. https://doi.org/10.1016/J.PHARMTHERA.2013.01.013.
Hoque, M., Samanta, A., Alam, S.S.M., Zughaibi, T.A., Kamal, M.A., Tabrez, S., Nanomedicine-based immunotherapy for Alzheimer’s disease. Neurosci. Biobehav. Rev. 2023. 144 https://doi.org/10.1016/J.NEUBIOREV.2022.104973.
Mortada, I., Farah, R., Nabha, S., Ojcius, D.M., Fares, Y., Almawi, W.Y., Sadier, N.S., Immunotherapies for Neurodegenerative Diseases. Front. Neurol. 2021. 12, 654739 https://doi.org/10.3389/FNEUR.2021.654739/BIBTEX.
Weihofen, A. et al., Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson’s disease models. Neurobiol. Dis. 2019. 124, 276–288. https://doi.org/10.1016/J.NBD.2018.10.016.
Imran, M et al., Exploring the Remarkable Chemotherapeutic Potential of Polyphenolic Antioxidants in Battling Various Forms of Cancer, 28, 3475 Mol 2023 Vol. 28, 3475. https://doi.org/10.3390/MOLECULES28083475.
Stratakis, E., Novel Biomaterials for Tissue Engineering 2018, 2018, Vol. 19, 3960 19 Int. J. Mol. Sci. 3960. https://doi.org/10.3390/IJMS19123960.
Bordoni, M., Scarian, E., Rey, F., Gagliardi, S., Carelli, S., Pansarasa, O., Cereda, C., Biomaterials in neurodegenerative disorders: a promising therapeutic approach. Int. J. Mol. Sci. 2020b 21 https://doi.org/10.3390/IJMS21093243.
Eleftheriadou, D., Kesidou, D., Moura, F., Felli, E., Song, W., 2020. Redox-responsive nanobiomaterials-based therapeutics for neurodegenerative diseases. Small 16. https://doi.org/10.1002/SMLL.201907308.
Shabani, L., Abbasi, M., Azarnew, Z., Amani, A.M., Vaez, A., Neuronanotechnology: diagnostic and therapeutic nano-based strategies in applied neuroscience, 2023 221 22, 1–41 Biomed. Eng. OnLine. https://doi.org/10.1186/S12938-022-01062-Y.
Schliebs,R. and Arendt T. Thecholinergic system in aging and neuronal degeneration. Behav. Brain Res. 2020b 221,555–563.doi:10.1016/j.bbr.2010.11.058
Posadas,I.,López-Hernández,B.,andCeña,V. Nicotinicreceptors in neurodegeneration. Curr. Neuro-pharmacol (2013) 11, 298–314. doi: 10.2174/1570159X11311030005
PuzzoD. and Arancio O Amyloid-β peptide: J. Alzheimers Dis. (2013). 33 (Suppl.1), S111–S120. doi:10.3233/JAD-2012-129033
Wang,H.Y. et al., Beta-Amyloid (1-42) binds to alpha 7 nicotinic acetylcholine receptor with high affinity Implications for Alzheimer’s disease pathology. J. Biol. Chem. (2000) 275, 5626–5632.doi:10.1074/jbc.275.8.5626
Ranilla, L.G.; Kwon, Y.-I.; Apostolidis, E.; Shetty, K. Phenolic Compounds, Antioxidant Activity and in Vitro Inhibitory Potential against Key Enzymes Relevant for Hyperglycemia and Hypertension of Commonly Used Medicinal Plants, Herbs and Spices in Latin America. Bioresour. Technol. 2010, 101, 4676–4689.
Lopes, G.; Gomes, E.; Barbosa, M.; Bernardo, J.; Valentão, P. Camel Grass Phenolic Compounds: Targeting Inflammation and Neurologically Related Conditions. Molecules 2022, 27, 7707.
Lee, B.K.; Hyun, S.-W.; Jung, Y.-S. Yuzu Hesperidin Ameliorate Blood-Brain Barrier Disruption during Hypoxia via Antioxidant Activity. Antioxidants 2020, 9, 843.
Fox, J.H.; Connor, T.; Stiles, M.; Kama, J.; Lu, Z.; Dorsey, K.; Lieberman, G.; Sapp, E.; Cherny, R.A.; Banks, M.; et al. Cysteine Oxidation within N-Terminal Mutant Huntingtin Promotes Oligomerization and Delays Clearance of Soluble Protein. J. Biol. Chem. 2011, 286, 18320–18330.
Bartzokis, G.; Lu, P.H.; Tishler, T.A.; Fong, S.M.; Oluwadara, B.; Finn, J.P.; Huang, D.; Bordelon, Y.; Mintz, J.; Perlman, S. Myelin Breakdown and Iron Changes in Huntington’s Disease: Pathogenesis and Treatment Implications. Neurochem. Res. 2007, 32, 1655–1664.
Zeb, A. Concept, Mechanism, and Applications of Phenolic Antioxidants in Foods. J. Food Biochem. 2020, 44, e13394.
Zamora, R.; Hidalgo, F.J. The Triple Defensive Barrier of Phenolic Compounds against the Lipid Oxidation-Induced Damage in Food Products. Trends Food Sci. Technol. 2016, 54, 165–174.
Li, Y.; Jongberg, S.; Andersen, M.L.; Davies, M.J.; Lund, M.N. Quinone-Induced Protein Modifications: Kinetic Preference for Reaction of 1,2-Benzoquinones with Thiol Groups in Proteins. Free Radic. Biol. Med. 2016, 97, 148–157.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 International Journal of Scientific Research in Science and Technology
This work is licensed under a Creative Commons Attribution 4.0 International License.
https://creativecommons.org/licenses/by/4.0
